GRB2 and neoplasm: The Grb2 splice variant Grb3-3 results in decreased activation of the Ras-MAPK pathway due competition with Grb2 for SOS binding, with reduced Grb3-3 levels observed in tumour tissue suggestive of a mechanism for enhancing Ras pathway activity.